Active Filter(s):
Details:
The proceeds will be used for creating a new class of medicines called molecular gates, which are small molecules and eliminate disease-causing extracellular proteins, drivers of diseases, ranging from inflammatory conditions to neurodegenerative disease to several cancers.
Lead Product(s): Molecular Gates
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 01, 2023